LEADER 02155nam  2200517   450 
001 9910816859303321
005 20230803030547.0
010   $a1-78084-195-7
035   $a(CKB)2670000000391294
035   $a(EBL)1179641
035   $a(OCoLC)851970663
035   $a(SSID)ssj0001599925
035   $a(PQKBManifestationID)16306389
035   $a(PQKBTitleCode)TC0001599925
035   $a(PQKBWorkID)14892908
035   $a(PQKB)11551135
035   $a(MiAaPQ)EBC1179641
035   $a(Au-PeEL)EBL1179641
035   $a(EXLCZ)992670000000391294
100   $a20220517d2013      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aCurrent & emerging treatments for immune thrombocytopenia /$feditor, Abdulgabar Salama
205   $a1st ed.
210  1$aLondon, England :$cFuture Medicine Ltd.,$d[2013]
210  4$dİ2013
215   $a1 online resource (135 p.)
300   $aDescription based upon print version of record.
311   $a1-78084-197-3 
327   $aTitle page; Copyright form; Contents; Foreword. Addressing current treatment options for autoimmune thrombocytopenia; 1. Pathogenesis; 2. Symptoms and diagnosis; 3. Treatment guidelines & algorithm; 4. Steroids; 5. Immunoglobulins; 6. Immunosuppressants; 7. Thrombopoietin receptor agonists; 8. Platelet transfusion; 9. Surgical approach; Index
330   $aImmune thrombocytopenia (ITP) is the best characterized human autoimmune disease and affects approximately 5% of the world's population. Clinically, it is defined by a low platelet count and increased bleeding risk. In this book, international experts provide a rounded overview of the disease and its management.
517 3 $aCurrent and emerging treatments for immune thrombocytopenia
606   $aThrombocytopenia
615  0$aThrombocytopenia.
676   $a616.157
702   $aSalama$b Abdulgabar
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910816859303321
996   $aCurrent & emerging treatments for immune thrombocytopenia$94127487
997   $aUNINA